Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

NCT05634525 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No participants enrolled

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: MRTX849

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]